JonesTrading analyst Soumit Roy maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report) on November 15 and set a price target of $5.00. The company’s shares closed last Wednesday at $0.67, close to its 52-week low of $0.59.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 24.5% and a 37.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
Aileron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $3.50, which is a 430.3% upside from current levels. In a report issued on November 12, H.C. Wainwright also maintained a Buy rating on the stock with a $2.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Aileron Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.7 million. In comparison, last year the company had a GAAP net loss of $5.02 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
Read More on ALRN:
- JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover
- Ionis Pharmaceuticals (IONS) Gets a Hold Rating from Leerink Partners
- Leerink Partners Keeps a Buy Rating on Dicerna Pharma (DRNA)
- B.Riley Financial Thinks Fusion Pharmaceuticals’ Stock is Going to Recover
- BTIG Sticks to Their Buy Rating for Washington Real Estate Investment (WRE)
